Breaking News

PPD Appoints Quality and Compliance Executive

March 25, 2013

Dixon brings 27 years of R&D experience

Jay Dixon has been appointed senior vice president of global quality and compliance at PPD. Mr. Dixon has more than 27 years of R&D experience in the pharmaceutical and biotechnology industries. Most recently, he was chief operating officer at PRACS Institute, with responsibility for providing strategic direction and leadership to the company’s service lines, quality infrastructure, management and business development activities. Previously, he served as senior vice president of regulatory affairs, quality and compliance, as well as chief compliance officer. Mr. Dixon has also served in quality and compliance roles with MedImmune, Abbott Laboratories, GlaxoSmithKline and two CROs.
 
“In today’s changing regulatory landscape, quality and compliance programs must continually evolve to meet and exceed international guidelines,” said David Simmons, PPD chairman and chief executive officer. “Jay’s combination of leadership skills and biopharmaceutical and contract research organization experience will enable PPD to continue fulfilling its commitment to providing superior quality and compliance solutions for clients.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important